National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
about
Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patientsGraft-versus-host disease affecting oral cavity. A reviewHow we treat chronic graft-versus-host disease.National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease.Modulation and Apoptosis of Neutrophil Granulocytes by Extracorporeal Photopheresis in the Treatment of Chronic Graft-Versus-Host Disease.Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group reporPredictive models for ocular chronic graft-versus-host disease diagnosis and disease activity in transplant clinical practice.Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity.How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationUptake and use of recommendations for the diagnosis, severity scoring and management of chronic GVHD: an international survey of the EBMT-NCI Chronic GVHD Task Force.Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.Evolving concepts in prognostic scoring of chronic GvHD.Classification systems for chronic graft-versus-host disease.Novel targets in the treatment of chronic graft-versus-host disease.NIH response criteria measures are associated with important parameters of disease severity in patients with chronic GVHD.Characterization and Risk Factor Analysis of Osteoporosis in a Large Cohort of Patients with Chronic Graft-versus-Host Disease.Clinical significance of autoantibodies in a large cohort of patients with chronic graft-versus-host disease defined by NIH criteria.NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT.Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients.Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10.Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.
P2860
Q26787230-08486791-AD44-47AE-8707-21450D2080DBQ27004303-191C58DA-F01E-4DB7-831B-0D3BD1301DD6Q35004923-1C5DFA92-36EE-4ECF-BBF9-A8F75121E0F4Q35085226-01C58D3E-46D7-46CF-A7C5-0F4CDFF9E075Q35571058-7302FA03-21BE-4411-AC2C-AD50AFA47CCFQ35588726-C6123C6D-2D08-4304-BABB-ADE595780260Q35737437-E23BD254-6661-404D-AADF-14A5070BE80DQ36554724-3B7CD8A9-3BA7-4B7D-8745-6C994D6E1272Q36708947-74C39F14-AF13-4C1D-9634-723FB0262C32Q37113099-56993E66-4128-4425-9CCB-D8DC6800DAA9Q37313795-6CEBD9BD-69AF-4CBD-9F4C-127C5371FBEBQ37609903-23D08AE6-B89F-4FB4-B97A-2964263DCE04Q37626094-F21F90FD-86D1-49B0-9157-0383D48294C0Q37656904-840839B3-3821-4E3C-B99A-3C3E1905902BQ38405625-118CF745-73C4-4FFA-84A0-B00572858778Q38739174-1DA91877-B452-45AA-9F07-F19EC9EC9216Q39002161-6AF5444C-E476-4448-A745-C292E652863BQ39023963-04F6237D-23C6-41FB-AC1C-E2E5C8B6D9A4Q39140290-3EB68EED-165D-4186-9F47-83684C686277Q39818593-0CC0C3A1-0390-454E-8C53-8A95CEEB1790Q41180891-635491D4-AD29-4938-8382-A46DFF23AC40Q41456444-ACA510B2-19AE-479E-A5C4-132455A3AAF1Q41529149-10683420-C428-4FE5-9EBD-A1C7EF1404DFQ41932903-2B3313FA-04E6-40AE-8ED8-6E19E152154DQ45866879-CA645B1B-1CD8-4BAD-B29F-72DE71E3A977Q49645938-5D8DF7BB-B11C-48DD-A041-E3CAACB43612Q52729477-5BCA7FFA-969B-4739-8B86-06978E804719
P2860
National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
National Institutes of Health ...... isease severity and prognosis.
@en
type
label
National Institutes of Health ...... isease severity and prognosis.
@en
prefLabel
National Institutes of Health ...... isease severity and prognosis.
@en
P2093
P2860
P1476
National Institutes of Health ...... disease severity and prognosis
@en
P2093
Amanda Urban
Ann Berger
Carol W Bassim
Claude Sportes
Daniel H Fowler
Daniele N Avila
Dean Edwards
Drazen Pulanic
Edward W Cowen
P2860
P304
P356
10.1016/J.BBMT.2013.01.013
P577
2013-01-20T00:00:00Z